Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients

[1] Gunderson K(2011)Global prostate cancer incidence and the migration, settlement, and admixture history of the Northern Europeans Cancer Epidemiol 35 320-327

[2] Wang CY(2014)Radical prostatectomy or watchful waiting in early prostate cancer N Engl J Med 370 932-942

[3] Wang R(2012)Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group BJU Int 109 22-29

[4] Bill-Axelson A(2004)Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer J Androl 25 305-313

[5] Holmberg L(2013)Picking the optimal duration of hormonal therapy in men with high-risk and locally advanced prostate cancer treated with radiotherapy Semin Radiat Oncol 23 206-214

[6] Garmo H(2006)Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer BJU Int 98 20-27

[7] Rider JR(2000)Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy J Urol 163 1743-1746

[8] Taari K(2000)Mortality and institutionalization following hip fracture J Am Geriatr Soc 48 283-288

[9] Busch C(2005)Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 154-164

[10] Nordling S(2014)Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis Endocrine 45 370-381

[1] Gunderson K(2011)Global prostate cancer incidence and the migration, settlement, and admixture history of the Northern Europeans Cancer Epidemiol 35 320-327

[2] Wang CY(2014)Radical prostatectomy or watchful waiting in early prostate cancer N Engl J Med 370 932-942

[3] Wang R(2012)Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group BJU Int 109 22-29

[4] Bill-Axelson A(2004)Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer J Androl 25 305-313

[5] Holmberg L(2013)Picking the optimal duration of hormonal therapy in men with high-risk and locally advanced prostate cancer treated with radiotherapy Semin Radiat Oncol 23 206-214

[6] Garmo H(2006)Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer BJU Int 98 20-27

[7] Rider JR(2000)Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy J Urol 163 1743-1746

[8] Taari K(2000)Mortality and institutionalization following hip fracture J Am Geriatr Soc 48 283-288

[9] Busch C(2005)Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 154-164

[10] Nordling S(2014)Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis Endocrine 45 370-381